A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Incyte Corporation
M.D. Anderson Cancer Center
Children's Oncology Group
Dana-Farber Cancer Institute
Ankara University
Fred Hutchinson Cancer Center
Vanderbilt-Ingram Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Neovii Biotech
Fred Hutchinson Cancer Center
Technische Universität Dresden
National Institutes of Health Clinical Center (CC)